SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Sarepta Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$17.73+0.63 (+3.68%)
Close on Oct 19, 2026
- Market cap
- $1.87B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
98.8%
Operating margin
-31.8%+72.6 pts over 5 years
Net margin
-32.5%+70.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +15.6% | +33.1% | +32.4% | +111.1% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -101.4% | -70.1% | -53.5% | |
| Return on assets | -76.6% | -23.1% | -19.5% | |
| Current ratio | 4.95 | 5.97 | 2.32 | |
| Interest coverage | -141.0× | -9.4× | 18.3× | |
| Capex to revenue | 98.5% | 15.2% | 4.6% | |
| Diluted shares | 49M | 78M | 100M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sarepta Therapeutics generated $1.68B from operations and spent $409.36M on capital expenditure, dividends and share buybacks. 94% of that went back into the business.
Generated
$1.68B
Used
$409.36M
Capital expenditure$384.35M94%Dividends$00%Share buybacks$25.01M6%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-32.5%
×Asset turnover0.60×
×Equity multiplier2.74×
=Return on equity, FY2025-53.5%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -32.5% | 0.60× | 2.74× | -53.5% |
| FY2024 | 12.4% | 0.53× | 3.03× | 19.7% |
| FY2023 | -43.1% | 0.39× | 5.14× | -86.2% |
| FY2022 | -75.4% | 0.30× | 4.78× | -107.2% |
| FY2021 | -59.7% | 0.23× | 3.63× | -49.6% |
| FY2020 | -102.6% | 0.22× | 3.04× | -70.1% |
| FY2019 | -187.8% | 0.22× | 1.87× | -77.3% |
| FY2018 | -120.2% | 0.20× | 1.62× | -39.7% |
| FY2017 | -32.8% | 0.18× | 1.54× | -9.0% |
| FY2016 | -4930.2% | 0.02× | 1.32× | -101.4% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
2of 7 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$713.41M
- Cash generatingOperating cash flow above zero-$205.48M
- Return on assets improvedROA up on the prior year7.2% → -18.0%
- Earnings backed by cashOperating cash flow above net income-$205.48M vs -$713.41M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.20 → 2.32
- No dilutionShare count did not rise108M → 100M
- Gross margin improvedGross margin up on the prior year– → 98.84%
- More efficientAsset turnover rose0.58 → 0.55